Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tabellini

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Cellular Biochemistry|May 13, 1999
Influence of different metal ions on the ultrastructure, biochemical properties, and protein localization of the K562 cell nuclear matrixL M Neri, R Bortul, M Zweyer, et al.
Leukemia|February 20, 2003
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulationR Bortul, P L Tazzari, A Cappellini, et al.
Leukemia|September 13, 2003
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cellsA M Martelli, P L Tazzari, G Tabellini, et al.
Leukemia|March 16, 2007
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretionP L Tazzari, G Tabellini, R Bortul, et al.
Transfusion|February 24, 2000
Nuclear matrix protein is released from apoptotic white cells during cold (1-6 degrees C) storage of concentrated red cell units and might induce antibody response in multiply transfused patientsA M Martelli, P L Tazzari, R Bortul, et al.
Leukemia|July 30, 2013
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potentialL M Neri, A Cani, A M Martelli, et al.
Leukemia|February 19, 2011
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemiaC Evangelisti, F Ricci, P Tazzari, et al.
Leukemia|October 5, 2011
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implicationsC Grimaldi, F Chiarini, G Tabellini, et al.
Leukemia|May 23, 2012
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemiaC Simioni, L M Neri, G Tabellini, et al.
Leukemia|November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signalingF Buontempo, E Orsini, L R Martins, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Cellular Biochemistry|May 13, 1999
Influence of different metal ions on the ultrastructure, biochemical properties, and protein localization of the K562 cell nuclear matrixL M Neri, R Bortul, M Zweyer, et al.
Leukemia|February 20, 2003
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulationR Bortul, P L Tazzari, A Cappellini, et al.
Leukemia|September 13, 2003
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cellsA M Martelli, P L Tazzari, G Tabellini, et al.
Leukemia|March 16, 2007
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretionP L Tazzari, G Tabellini, R Bortul, et al.
Transfusion|February 24, 2000
Nuclear matrix protein is released from apoptotic white cells during cold (1-6 degrees C) storage of concentrated red cell units and might induce antibody response in multiply transfused patientsA M Martelli, P L Tazzari, R Bortul, et al.
Leukemia|July 30, 2013
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potentialL M Neri, A Cani, A M Martelli, et al.
Leukemia|February 19, 2011
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemiaC Evangelisti, F Ricci, P Tazzari, et al.
Leukemia|October 5, 2011
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implicationsC Grimaldi, F Chiarini, G Tabellini, et al.
Leukemia|May 23, 2012
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemiaC Simioni, L M Neri, G Tabellini, et al.
Leukemia|November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signalingF Buontempo, E Orsini, L R Martins, et al.
Pageof 3